Charles Pitman CFA
Stock Analyst at Barclays
(4.48)
# 1,037
Out of 4,345 analysts
356
Total ratings
59.7%
Success rate
12.9%
Average return
Main Sectors:
Stocks Rated by Charles Pitman CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €48.00 → €50.00 | $38.12 | +31.16% | 15 | May 19, 2026 | |
| LON: 0NZT UCB SA | Reiterated: Buy | €310.00 | $245.05 | +26.50% | 129 | May 19, 2026 | |
| ETR: MRK Merck KGaA | Maintained: Hold | €130.00 | $129.50 | +0.39% | 18 | May 18, 2026 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 670.00 | $496.80 | +34.86% | 29 | May 11, 2026 | |
| EPA: BIM bioMérieux S.A. | Maintained: Hold | €100.00 → €90.00 | $73.00 | +23.29% | 5 | Apr 23, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Buy | €270.00 | $235.20 | +14.80% | 22 | Apr 23, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Maintained: Buy | €220.00 | $171.20 | +28.50% | 17 | Apr 23, 2026 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | €13.50 → €12.50 | $9.69 | +29.03% | 17 | Apr 22, 2026 | |
| SWX: BANB Bachem Holding AG | Maintained: Hold | CHF 60.00 → CHF 65.00 | $80.55 | -19.30% | 11 | Apr 10, 2026 | |
| SWX: SDZ Sandoz Group AG | Maintained: Hold | CHF 75.00 | $64.52 | +16.24% | 1 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €48.00 | $51.15 | -6.16% | 15 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $10.99 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $360.00 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €105.00 → €60.00 | $65.50 | -8.40% | 3 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 35.00 → CHF 33.00 | $37.45 | -11.88% | 5 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €700.00 → €850.00 | $710.90 | +19.57% | 26 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €120.00 → €125.00 | $158.10 | -20.94% | 30 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $675 → $757 | $821.37 | n/a | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $21 | $8.05 | n/a | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $215.40 | n/a | 1 | Jan 13, 2022 |
Bayer Aktiengesellschaft
May 19, 2026
Maintained: Buy
Price Target: €48.00 → €50.00
Current: $38.12
Upside: +31.16%
UCB SA
May 19, 2026
Reiterated: Buy
Price Target: €310.00
Current: $245.05
Upside: +26.50%
Merck KGaA
May 18, 2026
Maintained: Hold
Price Target: €130.00
Current: $129.50
Upside: +0.39%
Lonza Group AG
May 11, 2026
Maintained: Buy
Price Target: CHF 670.00
Current: $496.80
Upside: +34.86%
bioMérieux S.A.
Apr 23, 2026
Maintained: Hold
Price Target: €100.00 → €90.00
Current: $73.00
Upside: +23.29%
Sartorius Aktiengesellschaft
Apr 23, 2026
Maintained: Buy
Price Target: €270.00
Current: $235.20
Upside: +14.80%
Sartorius Stedim Biotech S.A.
Apr 23, 2026
Maintained: Buy
Price Target: €220.00
Current: $171.20
Upside: +28.50%
Grifols, S.A.
Apr 22, 2026
Maintained: Buy
Price Target: €13.50 → €12.50
Current: $9.69
Upside: +29.03%
Bachem Holding AG
Apr 10, 2026
Maintained: Hold
Price Target: CHF 60.00 → CHF 65.00
Current: $80.55
Upside: -19.30%
Sandoz Group AG
Mar 11, 2026
Maintained: Hold
Price Target: CHF 75.00
Current: $64.52
Upside: +16.24%
Feb 12, 2026
Upgraded: Hold
Price Target: €48.00
Current: $51.15
Upside: -6.16%
Jan 6, 2026
Upgraded: Buy
Price Target: n/a
Current: $10.99
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: n/a
Current: $360.00
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: €105.00 → €60.00
Current: $65.50
Upside: -8.40%
Jan 6, 2026
Maintained: Buy
Price Target: CHF 35.00 → CHF 33.00
Current: $37.45
Upside: -11.88%
Oct 31, 2025
Maintained: Buy
Price Target: €700.00 → €850.00
Current: $710.90
Upside: +19.57%
Oct 24, 2025
Maintained: Hold
Price Target: €120.00 → €125.00
Current: $158.10
Upside: -20.94%
Apr 28, 2025
Maintained: Buy
Price Target: $675 → $757
Current: $821.37
Upside: n/a
Jan 4, 2024
Upgraded: Buy
Price Target: $21
Current: $8.05
Upside: n/a
Jan 13, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $215.40
Upside: n/a